Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
作者信息
Bezerra Matheus F, Coelho-Silva Juan L, Nascimento Jessica C, Benicio Mariana T, Rocha Cintia R, Machado Cintia G, Rego Eduardo M, Bezerra Marcos A, Lucena-Araujo Antonio R, Beltrão Eduardo I
机构信息
Keizo Asami Immunopathology Laboratory, Federal University of Pernambuco, Recife, Brazil.
Department of Genetics, Federal University of Pernambuco, Recife, Brazil.
出版信息
Haematologica. 2017 Feb;102(2):e43-e46. doi: 10.3324/haematol.2016.155069. Epub 2016 Oct 20.
Abstract
摘要
相似文献
1
Association between the TP53 Arg72Pro polymorphism and clinical outcomes in acute myeloid leukemia.
Haematologica. 2017 Feb;102(2):e43-e46. doi: 10.3324/haematol.2016.155069. Epub 2016 Oct 20.
2
Idarubicin plus behenoyl cytarabine and 6-thioguanine compares favorably with idarubicin plus cytarabine-based regimen for children with previously untreated acute myeloid leukemia: 10-year retrospective, multicenter study in Korea.
J Korean Med Sci. 2010 Jan;25(1):9-15. doi: 10.3346/jkms.2010.25.1.9. Epub 2009 Dec 26.
3
TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Eur J Haematol. 2015 Apr;94(4):355-62. doi: 10.1111/ejh.12438. Epub 2014 Oct 1.
4
Acute myeloid leukemia presenting as non-neutropenic colitis in an infant.
J Pediatr Gastroenterol Nutr. 2003 Nov;37(5):631-3. doi: 10.1097/00005176-200311000-00025.
5
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience.
Am J Hematol. 2009 Oct;84(10):690-2. doi: 10.1002/ajh.21516.
6
Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine.
Clin Lymphoma Myeloma. 2009 Aug;9(4):E14-5. doi: 10.3816/CLM.2009.n.066.
7
Results of program acute myeloid leukemia therapy use in National Medical Research Center for Hematology of the Ministry of Health of Russian Federation.
Ter Arkh. 2018 Aug 17;90(7):14-22. doi: 10.26442/terarkh201890714-22.
8
Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.
Br J Haematol. 2017 Sep;178(5):810-812. doi: 10.1111/bjh.14166. Epub 2016 Jul 19.
9
Chromosomes and causation of human cancer and leukemia. IX. Prognostic and therapeutic value of chromosomal findings in acute myeloblastic leukemia.
Cancer. 1974 Jun;33(6):1548-57. doi: 10.1002/1097-0142(197406)33:6<1548::aid-cncr2820330612>3.0.co;2-m.
10
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Medicine (Baltimore). 2018 Sep;97(39):e12102. doi: 10.1097/MD.0000000000012102.
引用本文的文献
1
From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy.
Biomark Res. 2024 Nov 14;12(1):137. doi: 10.1186/s40364-024-00676-9.
2
Association Analysis of TP53 rs1042522, MDM2 rs2279744, rs3730485, MDM4 rs4245739 Variants and Acute Myeloid Leukemia Susceptibility, Risk Stratification Scores, and Clinical Features: An Exploratory Study.
J Clin Med. 2020 Jun 1;9(6):1672. doi: 10.3390/jcm9061672.
3
The TP53 Pro72Arg SNP in de novo acute myeloid leukemia.
Haematologica. 2017 May;102(5):e214-e215. doi: 10.3324/haematol.2017.165019.
本文引用的文献
1
Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies.
Sci Rep. 2016 Apr 7;6:24097. doi: 10.1038/srep24097.
2
Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia.
Br J Haematol. 2017 Feb;176(3):498-501. doi: 10.1111/bjh.13971. Epub 2016 Feb 23.
3
Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma - A case-control study.
Genet Mol Biol. 2015 Dec;38(4):444-9. doi: 10.1590/S1415-475738420140359. Epub 2015 Nov 24.
4
Acute Myeloid Leukemia.
N Engl J Med. 2015 Sep 17;373(12):1136-52. doi: 10.1056/NEJMra1406184.
5
Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting.
Blood. 2015 Oct 8;126(15):1863-5. doi: 10.1182/blood-2015-07-657551. Epub 2015 Aug 28.
6
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
N Engl J Med. 2013 May 30;368(22):2059-74. doi: 10.1056/NEJMoa1301689. Epub 2013 May 1.
7
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome.
Blood. 2012 Mar 1;119(9):2114-21. doi: 10.1182/blood-2011-08-375758. Epub 2011 Dec 20.
8
MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility.
Blood. 2008 Aug 1;112(3):741-9. doi: 10.1182/blood-2007-11-126508. Epub 2008 Apr 21.
9
Frequency of TP53 mutations in relation to Arg72Pro genotypes in non small cell lung cancer.
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2077-81. doi: 10.1158/1055-9965.EPI-07-0153.
10
Polymorphisms in the p53 pathway.
Oncogene. 2006 Mar 13;25(11):1602-11. doi: 10.1038/sj.onc.1209367.
Zotero 插件